Ver­tex adds a new gene edit­ing part­ner, pay­ing Ob­sid­i­an $75M for con­trol­lable CRISPR sys­tem

When Paul Wot­ton be­came CEO of Ob­sid­i­an Ther­a­peu­tics two years ago, he asked his team to ex­plore where they could ap­ply the com­pa­ny’s tech­nol­o­gy be­yond can­cer.

Launched by Michael Gilman in 2017, the GV-backed com­pa­ny had been work­ing on a way of con­trol­ling cell ther­a­pies af­ter they’re ad­min­is­tered to a pa­tient, al­low­ing doc­tors to mod­u­late the po­ten­cy of CAR-T and oth­er drugs as you might vol­ume on a tele­vi­sion set. Wot­ton want­ed to them look be­yond can­cer, in­to ar­eas such as gene edit­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER